Skip to main content
Top
Published in: Diabetologia 7/2006

01-07-2006 | Letter

Reply to comment on: Høi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B (2005) The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 48:2437–2438

Authors: T. Høi-Hansen, U. Pedersen-Bjergaard, B. Thorsteinsson

Published in: Diabetologia | Issue 7/2006

Login to get access

Excerpt

To the Editor: Thank you for giving us the opportunity to respond to the letter from Iseda et al. [1]. We certainly acknowledge the extensive scientific contribution made by Dr Somogyi [2]. He concluded, amongst other things, after studying five patients that ‘excessive glycosuria (hyperglycemia) is an aftermath of hypoglycemia’ [3]. With the years, this phrase has been interpreted as nocturnal hypoglycaemia inducing high morning blood glucose values [4]. In our letter we rejected this clinical statement by showing that if patients have a nocturnal hypoglycaemic episode during the night there was a high probability that blood glucose the following morning was low [5]. This finding suggests that hormonal counter-regulation alone is not capable of inducing hyperglycaemic excursions in type 1 diabetic patients. Iseda et al. now raise the question of whether hyperglycaemia occurs later on in the day after a nocturnal hypoglycaemic episode. In this context it should be noted that the glycaemic response during the day after a night with hypoglycaemia is a complex result of carbohydrate intake (sometimes increased by the hypoglycaemic episode), insulin dosage (possibly reduced if morning glucose is low), prolonged action of counter-regulatory hormones (primarily cortisol and growth hormone), physical activity and other factors. This means that a hyperglycaemic excursion after an episode of nocturnal hypoglycaemia may be caused by reasons other than pure counter-regulatory insulin resistance. Nevertheless, we consider the question to be of clinical importance and have looked further into our data by studying hourly glucose values determined by a continuous glucose monitoring system (CGMS) for 4 h post-breakfast (Fig. 1) and the maximum value during the day.
Literature
1.
go back to reference Iseda I, Lins PE, Adamson U, Kollind M (2006) Comment to: Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B (2005) The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 48:2437–24–38. Diabetologia. DOI:10.1007/s00125-006-0238-z Iseda I, Lins PE, Adamson U, Kollind M (2006) Comment to: Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B (2005) The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 48:2437–24–38. Diabetologia. DOI:10.1007/s00125-006-0238-z
5.
go back to reference Høi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B (2005) The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 48:2437–2438CrossRefPubMed Høi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B (2005) The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 48:2437–2438CrossRefPubMed
Metadata
Title
Reply to comment on: Høi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B (2005) The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 48:2437–2438
Authors
T. Høi-Hansen
U. Pedersen-Bjergaard
B. Thorsteinsson
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0284-6

Other articles of this Issue 7/2006

Diabetologia 7/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.